CapsulesClinical Overview
Tamsulosin Hydrochloride (0.4mg) and Tolterodine Tartrate (2mg/4mg Extended Release) Capsules is a fixed-dose combination for men suffering from mixed storage and voiding lower urinary tract symptoms (LUTS). Tamsulosin relieves voiding symptoms (hesitancy, weak stream, straining) via alpha-1A adrenergic blockade, while tolterodine competitively antagonizes muscarinic M2/M3 receptors in the detrusor muscle, abolishing involuntary bladder spasms and relieving storage symptoms (frequency, urgency, nocturia). Indicated for men with BPH and co-existing Overactive Bladder (OAB).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily after the same meal (preferably breakfast or dinner) with a glass of water. Swallow capsule whole without opening or crushing.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dry mouth, dizziness, abnormal ejaculation, constipation, dyspepsia, blurred vision, fatigue. Rare/Severe: Acute urinary retention (AUR), narrow-angle glaucoma attack, and QT interval prolongation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Monitor post-void residual (PVR) urine volume prior to starting therapy; contraindicated if baseline PVR exceeds 150-200 mL due to risk of precipitating acute urinary retention. Contraindicated in gastric retention, toxic megacolon, and uncontrolled narrow-angle glaucoma.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, nephrological diagnosis, or urological treatment recommendations. Always consult a registered nephrologist, urologist, or qualified medical practitioner before initiating, modifying, or discontinuing any kidney or urinary tract medication.
Tamsulosin Hydrochloride (Modified Release) 0.4mg + Dutasteride 0.5mg Tablets
Tamsulosin Hydrochloride (0.4mg modified-release) and Dutasteride (0.5mg) Tablets/Capsules is a synergistic dual-action therapy on the WHO Model List framework for symptomatic Benign Prostatic Hyperplasia (BPH). Tamsulosin is a uroselective alpha-1A/1D adrenergic receptor antagonist that relaxes smooth muscle in the prostate stroma, prostatic capsule, and bladder neck, rapidly improving urinary peak flow rates and relieving lower urinary tract symptoms (LUTS). Dutasteride is a potent dual type 1 and type 2 5-alpha reductase inhibitor (5-ARI) that suppresses dihydrotestosterone (DHT) synthesis by >90%, progressively shrinking enlarged prostate volume over 3-6 months. Indicated for moderate-to-severe BPH with enlarged prostate (volume >30cc) to reduce the risk of acute urinary retention (AUR) and the need for BPH-related surgery (TURP).
Tamsulosin Hydrochloride Prolonged Release Capsules 0.4mg
Tamsulosin Hydrochloride Prolonged Release Capsules (0.4mg) is a uroselective alpha-1A and alpha-1D adrenergic receptor antagonist on the WHO Model List of Essential Medicines. By selectively blocking alpha-1A receptors concentrated in the human prostate, bladder neck, and prostatic urethra (which account for 70% of prostatic alpha receptors), it relaxes smooth muscle tone, reduces outflow resistance, and enhances maximum urinary flow rate (Qmax) with minimal effect on systemic vascular resistance. Indicated for symptomatic Benign Prostatic Hyperplasia (BPH) and as off-label medical expulsive therapy for distal ureteric stones.
Tamsulosin Hydrochloride 0.4mg + Tolterodine Tartrate 2mg Extended Release Capsules
Tamsulosin Hydrochloride (0.4mg) and Tolterodine Tartrate (2mg/4mg Extended Release) Capsules is a fixed-dose combination for men suffering from mixed storage and voiding lower urinary tract symptoms (LUTS). Tamsulosin relieves voiding symptoms (hesitancy, weak stream, straining) via alpha-1A adrenergic blockade, while tolterodine competitively antagonizes muscarinic M2/M3 receptors in the detrusor muscle, abolishing involuntary bladder spasms and relieving storage symptoms (frequency, urgency, nocturia). Indicated for men with BPH and co-existing Overactive Bladder (OAB).
Tolterodine Tartrate Extended Release Capsules 2mg
Tolterodine Tartrate Extended-Release Capsules (2mg, 4mg) is a competitive muscarinic receptor antagonist on the WHO Model List framework for Overactive Bladder. It targets muscarinic M2 and M3 receptors in the urinary bladder with functional organ selectivity over salivary glands, suppressing involuntary detrusor contractions while allowing normal voluntary voiding. Indicated for treatment of Overactive Bladder with symptoms of urge urinary incontinence, urgency, and frequency.